Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry J M Groen

Showing results (111-120 of 274) with videos related to

Pageof 28
Sort By:
Psycho-Oncology|September 10, 2014
Distress in suspected lung cancer patients following rapid and standard diagnostic programs: a prospective observational studyPepijn Brocken, Erik H F M van der Heijden, Karen T M Oud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2012
A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutationAnne-Marie C Dingemans, Wouter W Mellema, Harry J M Groen, et al.
Cancers|January 5, 2018
Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung CancersJiacong Wei, Anthonie J van der Wekken, Ali Saber, et al.
Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinibLeora Horn, Scott Gettinger, D Ross Camidge, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2011
Progress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 yearsMiep A van der Drift, Henrike E Karim-Kos, Sabine Siesling, et al.
Clinical Lung Cancer|July 2, 2016
Cancer Stem Cells, Epithelial to Mesenchymal Markers, and Circulating Tumor Cells in Small Cell Lung CancerMilind Pore, Coby Meijer, Geertruida H de Bock, et al.
British Journal of Cancer|January 16, 2020
Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survivalAfroditi Nanou, M Craig Miller, Leonie L Zeune, et al.
Lung Cancer (Amsterdam, Netherlands)|January 11, 2015
Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensusFederico Cappuzzo, Denis Moro-Sibilot, Oliver Gautschi, et al.
JTO Clinical and Research Reports|June 19, 2025
Erratum to 'Model-Based Cost-Utility Analysis of Combined Low-Dose Computed Tomography Screening for Lung Cancer, Chronic Obstructive Pulmonary Disease, and Cardiovascular Disease' [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100813]Carina M Behr, Maarten J IJzerman, Michelle M A Kip, et al.
JTO Clinical and Research Reports|April 16, 2025
Model-Based Cost-Utility Analysis of Combined Low-Dose Computed Tomography Screening for Lung Cancer, Chronic Obstructive Pulmonary Disease, and Cardiovascular DiseaseCarina M Behr, Maarten J IJzerman, Michelle M A Kip, et al.
Pageof 28

Showing results (111-120 of 274) with videos related to

Sort By:
Pageof 28
Psycho-Oncology|September 10, 2014
Distress in suspected lung cancer patients following rapid and standard diagnostic programs: a prospective observational studyPepijn Brocken, Erik H F M van der Heijden, Karen T M Oud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2012
A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutationAnne-Marie C Dingemans, Wouter W Mellema, Harry J M Groen, et al.
Cancers|January 5, 2018
Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung CancersJiacong Wei, Anthonie J van der Wekken, Ali Saber, et al.
Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinibLeora Horn, Scott Gettinger, D Ross Camidge, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2011
Progress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 yearsMiep A van der Drift, Henrike E Karim-Kos, Sabine Siesling, et al.
Clinical Lung Cancer|July 2, 2016
Cancer Stem Cells, Epithelial to Mesenchymal Markers, and Circulating Tumor Cells in Small Cell Lung CancerMilind Pore, Coby Meijer, Geertruida H de Bock, et al.
British Journal of Cancer|January 16, 2020
Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survivalAfroditi Nanou, M Craig Miller, Leonie L Zeune, et al.
Lung Cancer (Amsterdam, Netherlands)|January 11, 2015
Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensusFederico Cappuzzo, Denis Moro-Sibilot, Oliver Gautschi, et al.
JTO Clinical and Research Reports|June 19, 2025
Erratum to 'Model-Based Cost-Utility Analysis of Combined Low-Dose Computed Tomography Screening for Lung Cancer, Chronic Obstructive Pulmonary Disease, and Cardiovascular Disease' [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100813]Carina M Behr, Maarten J IJzerman, Michelle M A Kip, et al.
JTO Clinical and Research Reports|April 16, 2025
Model-Based Cost-Utility Analysis of Combined Low-Dose Computed Tomography Screening for Lung Cancer, Chronic Obstructive Pulmonary Disease, and Cardiovascular DiseaseCarina M Behr, Maarten J IJzerman, Michelle M A Kip, et al.
Pageof 28